Skip to content
Screener

Maze Therapeutics MAZE Current ratio

Current ratio at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
3.2×+0.7×
Septerna, Inc. logo
Septerna, Inc.SEPN
5×-17.1×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
9×+0.6×
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
10.9×-4.3×
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
6.3×-0.5×
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
32.6×+16.8×

Other financials

Income statement

See full
Revenue$20.0M—
Operating income-$48.0M-31.7%
Net income-$44.7M-32.8%
EPS (diluted)-$0.76+1.3%

Balance sheet

See full
Cash & equivalents$202.6M-23.4%
Total debt$60.4M+142%
Total equity$453.1M+72.8%
Total assets$531.6M+75.2%

Cash flow

See full
Operating cash flow-$15.1M+49.9%
CapEx$107.0K-72.8%
Free cash flow-$15.2M+50.2%

Valuation

See full
Market cap$1.51B+156%
Enterprise value$1.37B+290%

Returns & leverage

See full
Return on equity-37.3%—
Debt / equity0.1×0.0×

Where this comes from

Calculated from Maze Therapeutics’s reported figures.

total current assets/total current liabilities=18.3×

Based on the most recent quarter.

The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 4:48 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344903

FAQ

What is Maze Therapeutics's current ratio?
Maze Therapeutics (MAZE) reported current ratio of 18.3× in Q2 2026.
How has Maze Therapeutics's current ratio changed year-over-year?
Maze Therapeutics's current ratio increased by 34.4% year-over-year, from 13.6× to 18.3×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.

Ask your AI about Maze Therapeutics's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude